BIOMAT Database Logo BIOMAT Database Logo

Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT. 2018

Saravanan Parthasarathy, and Kenneth Henry, and Huaxing Pei, and Josh Clayton, and Mark Rempala, and Deidre Johns, and Oscar De Frutos, and Pablo Garcia, and Carlos Mateos, and Sehila Pleite, and Yong Wang, and Stephanie Stout, and Bradley Condon, and Sheela Ashok, and Zhohai Lu, and William Ehlhardt, and Tom Raub, and Mei Lai, and Sandaruwan Geeganage, and Timothy P Burkholder
Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN 46285-0150, United States. Electronic address: shakthisarav@gmail.com.

During the course of our research efforts to develop potent and selective AKT inhibitors, we discovered enatiomerically pure substituted dihydropyridopyrimidinones (DHP) as potent inhibitors of protein kinase B/AKT with excellent selectivity against ROCK2. A key challenge in this program was the poor physicochemical properties of the initial lead compound 5. Integration of structure-based drug design and physical properties-based design resulted in replacement of a highly hydrophobic poly fluorinated aryl ring by a simple trifluoromethyl that led to identification of compound 6 with much improved physicochemical properties. Subsequent SAR studies led to the synthesis of new pyran analog 7 with improved cell potency. Further optimization of pharmacokintetics properties by increasing permeability with appropriate fluorinated alkyl led to compound 8 as a potent, selective AKT inhibitors that blocks the phosphorylation of GSK3β in vivo and had robust, dose and concentration dependent efficacy in the U87MG tumor xenograft model.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071679 Glycogen Synthase Kinase 3 beta A glycogen synthase kinase-3 type enzyme that functions in ENERGY METABOLISM; EMBRYONIC DEVELOPMENT; and NEUROGENESIS. It is also involved in PROTEIN BIOSYNTHESIS and regulates cell growth and proliferation as a component of the WNT SIGNALING PATHWAY and other signaling pathways. Certain polymorphisms in the GSK3B gene have been associated with PARKINSON DISEASE; ALZHEIMER DISEASE; and BIPOLAR DISORDER. GSK-3beta,GSK3B Protein,GSK3beta,GSK 3beta
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Saravanan Parthasarathy, and Kenneth Henry, and Huaxing Pei, and Josh Clayton, and Mark Rempala, and Deidre Johns, and Oscar De Frutos, and Pablo Garcia, and Carlos Mateos, and Sehila Pleite, and Yong Wang, and Stephanie Stout, and Bradley Condon, and Sheela Ashok, and Zhohai Lu, and William Ehlhardt, and Tom Raub, and Mei Lai, and Sandaruwan Geeganage, and Timothy P Burkholder
Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2.
July 2022, ACS medicinal chemistry letters,
Saravanan Parthasarathy, and Kenneth Henry, and Huaxing Pei, and Josh Clayton, and Mark Rempala, and Deidre Johns, and Oscar De Frutos, and Pablo Garcia, and Carlos Mateos, and Sehila Pleite, and Yong Wang, and Stephanie Stout, and Bradley Condon, and Sheela Ashok, and Zhohai Lu, and William Ehlhardt, and Tom Raub, and Mei Lai, and Sandaruwan Geeganage, and Timothy P Burkholder
Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors.
July 2016, ACS medicinal chemistry letters,
Saravanan Parthasarathy, and Kenneth Henry, and Huaxing Pei, and Josh Clayton, and Mark Rempala, and Deidre Johns, and Oscar De Frutos, and Pablo Garcia, and Carlos Mateos, and Sehila Pleite, and Yong Wang, and Stephanie Stout, and Bradley Condon, and Sheela Ashok, and Zhohai Lu, and William Ehlhardt, and Tom Raub, and Mei Lai, and Sandaruwan Geeganage, and Timothy P Burkholder
Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors.
June 2021, ACS medicinal chemistry letters,
Saravanan Parthasarathy, and Kenneth Henry, and Huaxing Pei, and Josh Clayton, and Mark Rempala, and Deidre Johns, and Oscar De Frutos, and Pablo Garcia, and Carlos Mateos, and Sehila Pleite, and Yong Wang, and Stephanie Stout, and Bradley Condon, and Sheela Ashok, and Zhohai Lu, and William Ehlhardt, and Tom Raub, and Mei Lai, and Sandaruwan Geeganage, and Timothy P Burkholder
Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors.
January 2008, Bioorganic & medicinal chemistry letters,
Saravanan Parthasarathy, and Kenneth Henry, and Huaxing Pei, and Josh Clayton, and Mark Rempala, and Deidre Johns, and Oscar De Frutos, and Pablo Garcia, and Carlos Mateos, and Sehila Pleite, and Yong Wang, and Stephanie Stout, and Bradley Condon, and Sheela Ashok, and Zhohai Lu, and William Ehlhardt, and Tom Raub, and Mei Lai, and Sandaruwan Geeganage, and Timothy P Burkholder
The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.
May 2009, Bioorganic & medicinal chemistry letters,
Saravanan Parthasarathy, and Kenneth Henry, and Huaxing Pei, and Josh Clayton, and Mark Rempala, and Deidre Johns, and Oscar De Frutos, and Pablo Garcia, and Carlos Mateos, and Sehila Pleite, and Yong Wang, and Stephanie Stout, and Bradley Condon, and Sheela Ashok, and Zhohai Lu, and William Ehlhardt, and Tom Raub, and Mei Lai, and Sandaruwan Geeganage, and Timothy P Burkholder
Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors.
August 2007, Bioorganic & medicinal chemistry letters,
Saravanan Parthasarathy, and Kenneth Henry, and Huaxing Pei, and Josh Clayton, and Mark Rempala, and Deidre Johns, and Oscar De Frutos, and Pablo Garcia, and Carlos Mateos, and Sehila Pleite, and Yong Wang, and Stephanie Stout, and Bradley Condon, and Sheela Ashok, and Zhohai Lu, and William Ehlhardt, and Tom Raub, and Mei Lai, and Sandaruwan Geeganage, and Timothy P Burkholder
Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.
June 2007, Journal of medicinal chemistry,
Saravanan Parthasarathy, and Kenneth Henry, and Huaxing Pei, and Josh Clayton, and Mark Rempala, and Deidre Johns, and Oscar De Frutos, and Pablo Garcia, and Carlos Mateos, and Sehila Pleite, and Yong Wang, and Stephanie Stout, and Bradley Condon, and Sheela Ashok, and Zhohai Lu, and William Ehlhardt, and Tom Raub, and Mei Lai, and Sandaruwan Geeganage, and Timothy P Burkholder
Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors.
January 2012, Bioorganic & medicinal chemistry letters,
Saravanan Parthasarathy, and Kenneth Henry, and Huaxing Pei, and Josh Clayton, and Mark Rempala, and Deidre Johns, and Oscar De Frutos, and Pablo Garcia, and Carlos Mateos, and Sehila Pleite, and Yong Wang, and Stephanie Stout, and Bradley Condon, and Sheela Ashok, and Zhohai Lu, and William Ehlhardt, and Tom Raub, and Mei Lai, and Sandaruwan Geeganage, and Timothy P Burkholder
Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
June 2013, Journal of medicinal chemistry,
Saravanan Parthasarathy, and Kenneth Henry, and Huaxing Pei, and Josh Clayton, and Mark Rempala, and Deidre Johns, and Oscar De Frutos, and Pablo Garcia, and Carlos Mateos, and Sehila Pleite, and Yong Wang, and Stephanie Stout, and Bradley Condon, and Sheela Ashok, and Zhohai Lu, and William Ehlhardt, and Tom Raub, and Mei Lai, and Sandaruwan Geeganage, and Timothy P Burkholder
Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors.
September 2017, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!